UNIGE document Scientific Article
previous document  unige:1856  next document
add to browser collection
Title

Double-blind studies are not always optimum for evaluation of a novel therapy: the case of new anticoagulants
Authors
Buller, Harry R.
Halperin, J L.
Bounameaux, Henri
Prins, M.
Published in Journal of Thrombosis and Haemostasis. 2008, vol. 6, no. 2, p. 227-9
Keywords Anticoagulants/standards/therapeutic use — Bias (Epidemiology) — Case Management — Clinical Trials, Phase III as Topic/methods/standards — Cost-Benefit Analysis — Double-Blind Method — Fibrinolytic Agents/standards/therapeutic use — Heparin/therapeutic use — Heparin, Low-Molecular-Weight/therapeutic use — Humans — Patient Selection — Professional Practice — Prothrombin Time/instrumentation — Quality of Life — Randomized Controlled Trials as Topic/methods/standards — Thrombophilia/drug therapy — Treatment Outcome — Vitamin K/antagonists & inhibitors
Identifiers
PMID: 18034770
Full text
Article (Author postprint) (72 Kb) - document accessible for UNIGE members only Limited access to UNIGE
Other version: http://www3.interscience.wiley.com/cgi-bin/fulltext/119422582/HTMLSTART
Structures
Faculté de médecine / Section de médecine clinique / Département de médecine interne des spécialités
Research groups Geneva Platelet Group (13)
La maladie thromboembolique veineuse (808)
Citation
(ISO format) 		BULLER, Harry R. et al. Double-blind studies are not always optimum for evaluation of a novel therapy: the case of new anticoagulants. In: Journal of Thrombosis and Haemostasis, 2008, vol. 6, n° 2, p. 227-9. https://archive-ouverte.unige.ch/unige:1856

175 hits

0 download

Contact an author

Update request

Update

Deposited on : 2009-06-02

Export document
Format :
Citation style :